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Chronic obstructive pulmonary disease (COPD) is a common global health problem with increasing incidence and
mortality. Therefore, attempting to increase the awareness of COPD and disseminate an effective system of
management for COPD is important for human health. The management of stable COPD should be based on the
disease severity, which is assessed by the severity of airflow limitation, symptoms and risk of exacerbations. The
current mainstay of COPD therapy is bronchodilators. Recent advances in the development of both long-acting
muscarinic receptor antagonists (LAMAs) and long-acting β2-adrenergic receptor agonists (LABAs) enable us to not
only improve lung function, symptoms and quality of life, but also decrease the frequency of exacerbations and
curb the rate of progression of airflow limitation. Because there are clinical phenotypes of COPD which have
increased airway inflammation, inhaled corticosteroids are likely considered for a supplemental medicine added to
an optimal long-acting inhaled bronchodilator regimen for frequent exacerbators and patients with the overlap
COPD-asthma phenotype. To establish novel COPD therapies that can considerably reduce the disease progression
and mortality as well as the comorbidities associated with COPD, new therapeutic targets that are involved in the
pathophysiology of COPD are being investigated.
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Chronic obstructive pulmonary disease (COPD) is a
major global health issue with constantly increasing inci-
dence and mortality. It is estimated that about 7 % of all
individuals have COPD. Especially, the prevalence is up
to 10 % in adults aged older than 65 years [1–5]. The ac-
tual prevalence would seem to be higher than that re-
ported because COPD is greatly under-diagnosed as well
as under-recognized. COPD is expected to become the
third leading cause of death worldwide by 2020 [6].
COPD is associated with a chronic inflammatory re-
sponse in the peripheral airways and lung parenchyma
to long-term exposure of noxious particles or gases. In
the majority of COPD cases, noxious agents in cigarette
smoke cause this chronic inflammation. Its pulmonary
component is characterized by airflow limitation that is
not thoroughly reversible and usually progressive. The* Correspondence: ichinose@rm.med.tohoku.ac.jp
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small conducting airways and increased compliance of
the lung as a result of emphysematous lesions [7].
The main symptoms of COPD are dyspnea and chronic
sputum production. Exertional dyspnea is the usual early
symptom of COPD. Although various factors are involved
in causing dyspnea, airway narrowing is a cardinal factor
associated with dyspnea [8–10]. Airway narrowing in
COPD is mainly caused by wall thickening and fibrosis in
the small airways, as well as collapse of the small airways
during exhalation due to the loss of radial traction caused
by breakdown of the lung alveolar tissue [11, 12]. The in-
creased sputum production is due to the increase in goblet
cells and mucus gland hyperplasia [13].
Because COPD cases have an irreversible airflow limi-
tation and their pathological condition is usually pro-
gressive throughout life, both pharmacological therapy
and nonpharmacologic therapies should aim to control
symptoms, improve quality of life, improve exercise tol-
erability, prevent exacerbations, disease progression andThis article is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
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cially, the recent report shows that dyspnea is the most
relevant factor inducing disability, decreasing dyspnea is
important to improve the ability of COPD patients [14].
To achieve these goals, both pharmacological therapy
and non-pharmacologic interventions including smoking
cessation, reduction of other risk factors, vaccinations,
oxygen therapy, and pulmonary rehabilitation should be
conducted with appropriate assessments of the disease
severity at the beginning of a patient's treatment as well
as continuous evaluation to determine whether the pa-
tient has achieved an adequate response to therapy. Re-
cent observations have supported the hypothesis that, in
COPD patients, the “spill-over” of inflammatory media-
tors from the lungs into the circulation may cause sys-
temic inflammation, which may initiate and worsen
ischaemic heart disease, heart failure, osteoporosis, nor-
mocytic anaemia, lung cancer, depression and diabetes
[15]. Therefore, appropriate control of the comorbidities
is also important for COPD patients [16, 17].
In this review, we provide an overview of the current
pharmacological therapies for the clinical management
of COPD, together with recent advances in long-acting
bronchodilators. We also discuss novel therapeutic tar-
gets for the future pharmacological therapy of COPD.
Review
Current pharmacological therapy for COPD
(1) Bronchodilators
Bronchodilators are the main pharmacological therapy for
patients with COPD. Bronchodilators should be added
according to the patient’s symptoms, risk of frequent
exacerbations and severity of the airflow limitation.
Bronchodilators can induce long-term improvements in
symptoms and exercise capacity, even if there is no or
only minimal spirometric improvement, because in-
haled bronchodilators reduce dynamic hyperinflation
during exercise in patients with COPD, resulting in im-
proved exercise endurance [18]. Moreover, the recent
report suggests that the effects of bronchodilators
should be evaluated from the changes of airway resist-
ance in the resting tidal volume range rather than
FEV1, especially in connection with the improvement
of dyspnea [19]. Therefore, the effect of therapies
should be determined based on not only forced
expiratory volume in one second (FEV1) but also
decreasing airway resistance and improvement of
hyperinflation, symptoms, health-related quality of
life (QOL), exercise endurance and physical activity of
the patients.
Bronchodilators can be administered by inhalation, or-
ally, percutaneously, subcutaneously, or intravenously. In-
halation is the recommended delivery method for COPD
patients because this way maximizes the bronchodilator'seffect on the airways while minimizing systemic side ef-
fects. Delivery methods for inhalation include a metered
dose inhaler (MDI), soft mist inhaler (SMI), dry powder
inhaler (DPI) or nebulizer. MDIs, SMIs, and DPIs enable
COPD patients to receive inhalation therapy more simply,
improving compliance and reducing the need for add-
itional medication. The choice of a delivery method for
inhalation should be determined after careful evaluation
of the COPD patient's clinical condition (degree of airway
obstruction, comorbidities) as well as their ability to man-
euverer an inhalation device and to generate sufficient in-
spiratory flow. These patient factors should be adjusted
with the advantages and limitations of each inhaler [20].
Bronchodilators include β2 agonists, anticholinergics,
and also methylxanthine, which is not typically used
these days. Because each bronchodilator has a different
mechanism of action, the addition of other bronchodila-
tors can be considered when monotherapy is inadequate
to improve the symptoms of COPD patients. β2 agonists
activate β2-adrenergic receptors on airway smooth
muscle [21]. Because β2-adrenergic receptors are
coupled to a stimulatory G protein of adenylyl cyclase,
this activation increases the intracellular level of cAMP,
resulting in decreased calcium concentrations within
cells and the activation of protein kinase A. Those
changes inactivate myosin light chain kinase and activate
myosin light chain phosphatase. Moreover, β2-agonists
open large conductance calcium-activated potassium
channels, which induces hyperpolarization of the airway
smooth muscle cells. These changes lead to smooth
muscle relaxation and bronchodilation. Anticholinergics
(muscarinic receptor antagonists (MRAs)) block the ac-
tivity of the muscarinic acetylcholine receptor M3 on
smooth muscle cells and submucosal glands [22]. This
reduces smooth muscle contraction and mucus secre-
tion, resulting in bronchodilation. A methylxanthine is a
competitive, nonselective phosphodiesterase inhibitor
that increases the intracellular cAMP level and activa-
tion of protein kinase A, resulting in smooth muscle re-
laxation and bronchodilation [23].
(a) Short-acting bronchodilators
Short-acting β2 agonists and anticholinergics can be
used for COPD patients with mild intermittent symp-
toms [24, 25]. The onset of action by short-acting beta
agonists is relatively rapid compared to anticholinergics,
whereas the maximal efficacy of short-acting anticholin-
ergics for bronchodilation in COPD patients is better
than that of β2 agonists. Combination therapy may be
better because the combined use of a short-acting beta
agonist with a short-acting anticholinergic achieves a
greater bronchodilator response than either one alone
[26], though monotherapy with a short-acting broncho-
dilator is also effective and acceptable.
Table 1 Summary of long-acting bronchodilators including combinations
Dosing Reported superiority over other long-acting bronchodilators or ICSs References
LAMAs
Tiotropium once-daily vs. salmeterol: trough FEV1, improving dyspnea, health-related QOL,
preventing exacerbations
27–40
Glycopyrronium once-daily 41, 42




Indacaterol once-daily vs. salmeterol or formoterol: trough FEV1 and improving dyspnea 50–53
Olodaterol once-daily vs. formoterol: health-related QOL 54–56
LABA/LAMA
Umeclidinium once-daily vs. umeclidinium or vilanterol: trough FEV1, improving dyspnea, health-related QOL 60–63
-Vilanterol
Indacaterol once-daily vs. tiotropium: trough FEV1, improving dyspnea, health-related QOL, preventing
exacerbations; vs. glycopyrronium: trough FEV1, health-related QOL, preventing






twice-daily vs. salmeterol or fluticasone: trough FEV1, health-related QOL, preventing
exacerbation
48, 76, 77






once-daily vs. fluticasone furoate: trough FEV1 80
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(b)-1 Long-acting anticholinergics The long-acting an-
ticholinergics (long-acting muscarinic agents (LAMAs))
include tiotropium, glycopyrronium, aclidinium and
umeclidinium. These agents have higher selectivity for
M3 receptors than for M2 receptors and dissociate more
slowly from the M3 receptors, which can provide
longer-lasting bronchodilation [27–29].
Tiotropium is a once-daily long-acting anticholinergic
agent with M1 and M3 selectivity, and has been the
most studied agent for COPD. Studies have shown that
tiotropium improved lung function (an increase of both
trough FEV1 and forced vital capacity (FVC)) and exercise
endurance as well as health-related QOL, and reduced
dyspnea and the risk of COPD exacerbations [30–36].
Studies have also suggested that tiotropium may slow the
rate of decline in FEV1 in patients with moderate COPD
[37–39]. In terms of safety issues, there is conflicting evi-
dence of adverse cardiovascular effects from tiotropium.
Recent meta-analyses suggested that the tiotropium Soft
Mist Inhaler (Respimat®) was associated with a signifi-
cantly increased risk of mortality [40, 41]. This risk was
apparent for cardiovascular death in patients with severe
COPD, and at a higher daily dose [41]. However, data
from a long-term, randomized trial showed that tiotro-
pium was superior in reducing all causes of mortality by11 % compared with placebo [42]. Another more recent
randomized, double-blind, parallel-group trial revealed no
safety issues with the device, supporting the safety of the
Soft Mist Inhaler device [43].
Glycopyrronium is a once-daily long-acting anticholin-
ergic agent that also selectively inhibits muscarinic recep-
tors with M1 and M3 selectivity [27]. It also significantly
improves lung function (through FEV1) and dyspnea and
reduces exacerbations of COPD [44, 45].
Aclidinium is a twice-daily long-acting anticholinergic
that selectively inhibits M3 muscarinic receptors [28].
Since aclidinium is shorter acting than tiotropium,
twice-daily dosing is needed for better efficacy. Several
trials showed significant improvements in the trough
and peak FEV1 [46]. Aclidinium also improves dyspnea
and delayed the time to first exacerbation compared to
the placebo control [46, 47].
Umeclidinium is a once-daily LAMA that acts prefer-
entially on muscarinic M3 receptors, similar to tiotro-
pium. It significantly increases the trough FEV1 and also
reduces rescue SABA use [48]. Umeclidinium was been
developed for use in a combination inhaler with long-
acting LABA vilanterol.
(b)-2 Long-acting β2-agonists The long-acting β2-ago-
nists (LABAs) include salmeterol, formoterol, indacaterol,
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anticholinergic was preferred over a long-acting β2-
agonist because LAMAs, which act effectively for 24 h
by once daily dosing, seemed to be superior to LABAs,
which required twice-daily dosing for better effects.
Now that daily LABAs are available, the initial selection
of a long acting bronchodilator is based on co-morbid-
ities and side effects.
Salmeterol and formoterol are twice-daily LABAs used
in the maintenance for COPD. Formoterol has a faster on-
set of action than salmeterol, and has also been demon-
strated to be more potent. Both salmeterol and formoterol
significantly improved lung function as well as dyspnea,
decreased exacerbation rates and improved health-related
quality of life compared to placebo [49–52].
Indacaterol is a once-daily LABA with a rapid onset
and 24-h duration of bronchodilation. Indacaterol's
long duration of action may be related to its high affin-
ity for the lipid raft domain of the cell membrane [53].
Randomized controlled trials showed that indacaterol
significantly improved the trough FEV1 [54–56]. Inda-
caterol improved dyspnea and decreased the rate of ex-
acerbations in COPD patients. The trials also showed
that once-daily indacaterol was significantly more ef-
fective than twice-daily salmeterol or formoterol in
terms of improving the lung function and reducing dys-
pnea [54, 56].
Olodaterol is a once-daily LABA with a rapid onset
and long duration of action and is approved for the
treatment of COPD in Europe and US. It is delivered via
a soft mist inhaler. Clinical trials showed that olodaterol
improved lung function including peak and trough FEV1
and quality of life [57–59]. Adverse events with oloda-
terol were comparable to those of placebo.
Vilanterol is also a once-daily LABA with a rapid onset
and long duration of action. However, so far, it is not
available as a monotherapy. Vilanterol has been devel-
oped for combination inhalers with umeclidinium or flu-
ticasone furoate.
(b)-3 Comparison between LAMAs and LABAs
Because both LABAs and LAMAs are once-daily agents
with a long acting duration, the question of which type is
better for COPD patients may arise in the clinical setting.
A randomized controlled trial has done the compared a
once-daily LABA, indacaterol and a once-daily LAMA,
tiotropium. A trial in which moderate-to-severe COPD
patients were enrolled and observed over 26 weeks,
showed that indacaterol significantly improved the trough
FEV1 and at 12 weeks was superior to tiotropium, whereas
indacaterol lost this superiority at 26 weeks, though the ef-
fects of indacaterol and tiotropium on the trough FEV1
were maintained in terms of differing from placebo [55].
This trial also showed that indacaterol improved dyspnoea(transitional dyspnoea index (TDI)) and health-related
QOL (St. George’s Respiratory Questionnaire (SGRQ))
better than tiotropium. In terms of reducing exacerba-
tions, indacaterol did not appear superior to tiotropium.
The two treatments were well tolerated and had similar
adverse event profiles. Another randomized controlled
trial in which moderate-to-severe COPD patients were en-
rolled and observed for 12 weeks, revealed that indaca-
terol significantly improved dyspnoea and health-related
QOL, and reduced the use of rescue SABA compared to
tiotropium, though there was no significant difference in
FEV1 between indacaterol and tiotropium at 12 weeks
[60]. There was a randomized controlled trial in which pa-
tients with severe COPD and a history of at least one
moderate to severe exacerbation in the previous 12 months
were enrolled. This trial showed that both indacaterol and
tiotropium similarly improved the trough FEV1 as well as
providing protection from exacerbations [61]. These trials
suggested that once-daily indacaterol was at least as effect-
ive as a once-daily tiotropium in improving the clinical
outcomes of patients with COPD.
(b)-4 Combination therapies Another type of long
acting bronchodilator is additionally prescribed for
COPD patients whose symptoms are not well-controlled
with a single long-acting bronchodilator. A meta-
analysis of five trials that assessed a combination therapy
with a LAMA (tiotropium) plus a LABA (salmeterol,
formoterol, or indacaterol) showed that a combination
therapy provided only a small increase in the peak FEV1
and a slightly better quality of life compared to tiotro-
pium alone [62]. No difference was noted in exacerba-
tions, symptom scores, or serious adverse events.
Recently, a combination umeclidinium-vilanterol dry
powder inhaler has been approved for once-daily use for
COPD. Clinical trials showed that umeclidinium-
vilanterol increased the trough FEV1 significantly more
than umeclidinium, tiotropium or vilanterol monotherapy
[63–66]. The combination inhaler also provided greater
improvements in health-related QOL, and dyspnea scores
compared with its mono-components and placebo [63].
The effectiveness of umeclidinium-vilanterol for the re-
duction of COPD exacerbations seemed to be similar to
that of umeclidinium monotherapy [65].
Another once-daily dry powder inhaler containing the
combination of indacaterol-glycopyrronium has been re-
cently approved for COPD patients. The indacaterol-
glycopyrronium combination inhaler was found to be
superior to monotherapy with glycopyrronium, indaca-
terol, or tiotropium in terms of trough FEV1 [67–69].
Indacaterol-glycopyrronium also decreased the use of
rescue medication and risk of exacerbation, and im-
proved the health-related QOL compared to monother-
apy with glycopyrronium or tiotropium [68].
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Methylxantine is another option which may be consid-
ered as an additional therapy to bronchodilators and in-
haled corticosteroids. Slow-release oral theophylline is
usually used for COPD patients. Its bronchodilation ef-
fect is modest compared to inhaled bronchodilators. For
effective bronchodilation, the plasma levels of theophyl-
line needed to be in the 10 to 20 μg/ml range. Because
theophylline can be toxic, close monitoring of the drug
levels is required. In recent years, it has been reported
that low-dose theophylline (about 5 μg/ml at plasma
level) has anti-inflammatory effects in patients with
COPD [70–73]. This anti-inflammatory effect is likely
due to increasing HDAC2 expression and activity in the
alveolar macrophages of patients with COPD [74–77].
(2) Inhaled corticosteroids
COPD is an inflammatory disorder characterized by
both airway and systemic inflammation. Because inhaled
corticosteroid (ICS) therapy appears to reduce the in-
flammation, it has been hypothesized that ICS therapy
may improve clinical outcomes of COPD. A number of
clinical trials, including the largest randomized con-
trolled trial, found that ICS monotherapy decreased ex-
acerbations and modestly slowed the progression of
dyspnoea, but had minimal or no impact on lung func-
tion and survival in COPD patients [51, 78]. Therefore,
ICS therapy should be added to basic treatment with
bronchodilators for appropriate clinical phenotypes of
COPD, not recommended as monotherapy for patients
with stable COPD. These clinical phenotypes which
need additional treatment of ICS include frequent
exacerbators and patients with the overlap COPD-
asthma phenotype because lung inflammation is promin-
ent in these phenotypes [79, 80].
Previous trials suggested that ICS could be considered
as part of a combined therapy with bronchodilators for
the inhibition of COPD exacerbations in severe/very se-
vere patients. In one trial, salmeterol plus fluticasone
significantly improved lung function, health-related
QOL, and reduced the rate of exacerbations compared
to placebo, salmeterol alone, or fluticasone alone [51]. In
another clinical trial, 1323 COPD patients with stable,
mostly severe COPD were enrolled and randomly
assigned to receive salmeterol plus fluticasone or tiotro-
pium alone for two years. There was no difference in the
frequency of exacerbations, though salmeterol plus fluti-
casone reduced mortality and improved health-related
QOL [81]. On the other hand, a subsequent analysis of
this trial revealed that pneumonia was significantly more
frequent in the salmeterol plus fluticasone group, despite
the lower mortality [82]. It has also been shown that an-
other twice-daily combination inhaler, budesonide/for-
moterol, increased the trough FEV1 with a significantlygreater improvement than formoterol alone. The bude-
sonide/formoterol group had a significantly prolonged
time to first exacerbation versus the formoterol group
and significantly greater improvements in secondary out-
comes including symptom and health-related QOL [83, 84].
In addition to twice-daily combination inhalers, a once
daily dry powder inhaler, containing fluticasone furoate
and vilanterol, has been approved for the treatment of
COPD in US. A multicenter, 24-week trial in which stable
moderate-to-severe COPD patients were enrolled and
randomly assigned to fluticasone-vilanterol, fluticasone,
vilanterol, or placebo, showed that fluticasone-vilanterol
modestly reduced the rates of moderate and severe ex-
acerbation more than vilanterol alone [85]. The rate of
pneumonia was increased in the fluticasone-vilanterol
combination groups [85].
Because LAMAs have also been shown to prevent ex-
acerbations [36, 39, 81] and two types of long-acting
bronchodilators, LABA and LAMA, including a combin-
ation medication, are now prescribed for severe COPD
patients, whether inhaled corticosteroids provided sig-
nificant additional benefits to severe COPD patients who
are treated with both two types of long-acting broncho-
dilators remained unclear. To address this question, the
latest 12-month randomized-controlled trial studied
2485 severe COPD patients who had a history of exacer-
bations of COPD [86]. The patients received triple ther-
apy consisting of tiotropium, salmeterol and fluticasone
propionate during a 6-week run-in period. The patients
were then randomly assigned to continued triple therapy
or withdrawal of fluticasone in three steps over a 12-
week period and were observed until week 52. The re-
sults showed that the corticosteroid-withdrawal group
did not show worse results in preventing exacerbations
and improving dyspnea than the corticosteroid-
continuation group, though there were minor changes
in the FEV1 and health status in the corticosteroid-
withdrawal group at week 52. This report suggests the
possibility that additional ICS may not be needed for
reducing the risk of COPD exacerbations if the severe
COPD patients are treated with LABA and LAMA,
though it is also possible that the necessity of additional
ICS may depend on a COPD phenotype which is more
inflamed or not.
(3) PDE-4 inhibitors
Phosphodiesterase 4 (PDE-4) belongs to the cyclic nu-
cleotide phosphodiesterase (PDE) family and has four
gene families (A–D) [87]. As other PDEs, PDE-4 hydro-
lyzes cyclic adenosine monophosphate (cAMP). PDE-4
inhibitors block the hydrolysis of cAMP, resulting in in-
creased levels of cAMP within the cells. It has been
shown that inhibition of PDE-4 decreases inflammation
and may promote airway smooth muscle relaxation.
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for COPD patients in the United States. Randomized
controlled trials and a meta-analysis were performed to
investigate the effects of PDE-4 inhibitors. A randomized
controlled trial in which 3091 patients with COPD en-
rolled showed that Roflumilast significantly improved
the trough FEV1 and decreased the rate of moderate to
severe exacerbations during the 52 week trial [88]. In an-
other trial, 933 patients with moderate to severe COPD
were enrolled in and randomly assigned to roflumilast
plus salmeterol or salmeterol alone and 743 patients
were randomly assigned to roflumilast plus tiotropium
or tiotropium alone [89]. Roflumilast significantly im-
proved the trough FEV1, though such side effects of nau-
sea, diarrhea, and weight loss were more frequent in the
roflumilast groups. A meta-analysis of 23 randomized
trials of roflumilast or cilomilast (another PDE-4 inhibi-
tor) versus placebo found that treatment with a PDE-4
inhibitor modestly improved FEV1 and reduced the risk
of exacerbations but had little effect on the health-
related QOL [90]. Those studies suggest that oral PDE-4
inhibitors may be considered as an additional mainten-
ance therapy for patients with severe COPD forFig. 1 Therapeutic targets for future pharmacological therapy of COPD. Rece
new therapeutic targets for COPD patients. These possible therapeutic approa
cytokines or chemokines, inhibitors for pro-inflammatory kinase, antiproteases
JAK: janus kinase; MAPK: mitogen-activated kinase; NRF-2: NF-E2-related factor
phosphoinositide 3-kinasepreventing exacerbations. It has not been determined
whether it provides additional benefits when combined
with other medications (LABA and LAMA, or LABA
and inhaled corticosteroids).
Novel therapeutic targets for the future
pharmacological therapy of COPD
An important goal of COPD management is to reduce dis-
ease progression, prevent exacerbations, and reduce the
mortality rate. Although recent advances in bronchodila-
tors have enabled significant bronchodilation effects and
improvement of the symptoms and quality of life, current
therapies including long-acting bronchodilators fail to
substantially reduce disease progression, mortality and the
risk of exacerbations because bronchodilators don’t have
significantly anti-inflammatory effects. It has been shown
that COPD is associated with chronic inflammation in
peripheral airways and lung parenchyma as well as sys-
temic inflammation causing comorbidities including car-
diovascular diseases. Therefore, it is natural that effective
anti-inflammatory treatment would be necessary for redu-
cing the disease progression and the mortality of COPD
patients. However, no current therapies including inhalednt advances in the research of underlying chronic inflammation provide
ches include new antioxidants, inflammasome inhibitors, antagonists of
, and epigenetic modulation. IKK: inhibitor of NF-κB kinase; IL: interleukin;
; NLRP3: NOD-like receptor family, pyrin domain containing 3; PI3K:
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to treat the underlying inflammation in COPD patients.
Recent advances in the research of the underlying in-
flammation have been suggesting new therapeutic tar-
gets for anti-inflammatory treatments in COPD patients
(Fig. 1) [91]. These possible therapeutic approaches
include new antioxidants, inflammasome inhibitors, an-
tagonists of cytokines or chemokines, inhibitors for pro-
inflammatory kinase, antiproteases, reversal of steroid
resistance, and epigenetic modulation, some of which
are undergoing clinical trials.
It has been suggested that there are barriers to estab-
lishing new therapeutic approaches for COPD [91, 92].
These barriers include incomplete understanding of the
underlying mechanisms of COPD, lack of an appropri-
ate animal model, the heterogeneity of the disease, lack
of biomarkers for predicting therapeutic response and
long-duration trials needed for demonstration of clin-
ical efficacy. Moreover, it is also important to accom-
plish complete pathophysiological evaluation and
characterization of COPD patients to select an appro-
priate treatment for each clinical phenotype of COPD
in order to achieve the best management. Therefore,
further investigations for better understanding of the
biological and pathophysiological processes of COPD
are needed to achieve the goal of COPD management.
Conclusion
Recent advances in the development of long-acting
bronchodilators have enabled significantly improvements
in the symptoms and lung function of COPD patients.
These reagents also reduce the risk of exacerbation and
the rate of the progression of airflow limitation to some
extent. To establish novel COPD therapies that can sub-
stantially reduce disease progression, mortality and the
comorbidities, new therapeutic approaches that can re-
solve the underlying chronic inflammation and lung
pathophysiological modifications in COPD are needed,
and are being investigated.
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